300199.SZHybio Pharmaceutical Co., Ltd.
Hybio Pharmaceutical Co., Ltd. (300199.SZ) is a China-based company primarily engaged in the research, development, production, and sale of specialty and generic pharmaceutical products. The next catalyst is Nov 18, 2026 — US API Tariff & Trade Policy Update, which will test the company’s exposure to U.S. regulatory shifts impacting its export and import operations.
- The company operates in the drug manufacturing sector, with a focus on specialty and generic drugs.
- Its revenue is heavily reliant on international markets, particularly the U.S.
- The firm has a complex capital structure with significant debt, which could be tested by upcoming refinancing events.
The schedule
- Tue27Oct
Quarterly earnings release with guidance for FY 2026 and 2027
- Wed18Nov
The policy update tests the issuer's exposure to trade tariffs and its ability to hedge or adjust pricing, differing from the last print where the outcome was driven by macroeconomic sentiment rather than direct policy shifts.
- Thu15Apr
The earnings report tests the issuer's ability to meet or exceed guidance, with a focus on margin expansion and revenue growth, unlike the last print where the outcome was heavily influenced by macroeconomic uncertainty.
- Tue27Apr
The Q4 earnings release tests the issuer's ability to deliver consistent revenue and margin performance, with a focus on operational efficiency, differing from the last print where the outcome was influenced by broader market volatility.
- Thu10Jun
The update tests the issuer's ability to refinance debt at favorable rates and maintain a healthy capital structure, differing from the last print where the outcome was influenced by broader market sentiment.
- Tue27Jul
The Q1 earnings release tests the issuer's ability to deliver consistent revenue and margin performance, with a focus on operational efficiency, differing from the last print where the outcome was influenced by broader market volatility.
- Tue26Oct
The Q2 earnings release tests the issuer's ability to deliver consistent revenue and margin performance, with a focus on operational efficiency, differing from the last print where the outcome was influenced by broader market volatility.
- Tue25Jan
The Q3 earnings release tests the issuer's ability to deliver consistent revenue and margin performance, with a focus on operational efficiency, differing from the last print where the outcome was influenced by broader market volatility.
Past
- Fri28Aug
Actual outcome: Mixed · $22.77 at outcome
The company matched earnings expectations with an EPS of 0.14, but the stock fell 3.1% as guidance signaled continued margin pressure and a heavy debt burden. The market reacted negatively to the lack of upside surprise and concerns about sustaining the Q1 growth amid financial challenges.
Market reaction to Q2/1H results, testing the sustainability of Q1's 82% net income growth against a heavy debt burden.